CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 222 enrolled
Drug / intervention
Caspofungin +1 moredrug
Likely dose
Caspofungin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00520234
NCT00520234Phase 4Completed
CompareCT.gov

A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting

Mycoses Study Group·interventional·Posted Aug 23, 2007·Updated May 9, 2011

In Brief

A Phase 4 clinical trial evaluating Caspofungin and Normal Saline for Invasive Candidiasis. Completed, enrolled 222 participants across 12 sites.

Detailed Summary

Adults admitted to intensive care units are at risk for a variety of complications. Infections due to the fungus called candida are of particular concern. The study will test the possibility that caspofungin, a new therapy for fungal infections, can successfully reduce the rate of candida infections in subjects at risk. It will also test if caspofungin is useful in treating subjects for this disease when diagnosed using a new blood test that is performed twice weekly, permitting earlier diagnosis than current practice standards.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Candidiasis
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2007
Enrollment StartAug 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.9 years ago

Interventions

Caspofungindrug

50 mg IV daily

Normal Salinedrug

100 cc IV daily